Lifevantage Q4 Earnings Call Highlights

Revenue and profitability declined: Fourth-quarter revenue fell 23.1% year over year to $42.4 million, pressured by fewer orders, smaller order sizes and weaker MindBody GLP-1 System sales. Adjusted EBITDA dropped to $2.7 million from $4.8 million.

New CEO is prioritizing a turnaround: Terrence Moorehead plans to strengthen the brand, clarify the consumer product proposition, improve sales-force tools and boost operational efficiency. LifeVantage did not provide fiscal 2027 guidance because of the leadership transition.

Financial position remains stable: The company ended fiscal 2026 with $14.9 million in cash, no debt and access to a $5 million credit line, while continuing share repurchases and paying a quarterly dividend of $0.05 per share.

Lifevantage NASDAQ: LFVN reported lower fourth-quarter and fiscal 2026 results as the health and wellness company faced fewer orders, lower average order sizes and a difficult comparison against prior-year sales of its MindBody GLP-1 System.

For the fourth quarter ended June 30, net revenue declined 23.1% to $42.4 million from $55.1 million in the prior-year period. Revenue fell 3.1% sequentially from the fiscal third quarter.

The Americas region posted a 24.8% decline in revenue to $32.7 million, while Asia-Pacific and Europe revenue decreased 16.9% to $9.7 million.

Chief Financial Officer Carl Aure said the revenue decline primarily reflected pressure on order volumes from the active account base and lower average order size.

The results also reflected lower MindBody GLP-1 System sales against a stronger prior-year comparison, partly offset by contributions from LoveBiome, which LifeVantage acquired in October 2025.

More than 75% of fourth-quarter revenue came from subscriptions, Aure said, while customer retention metrics improved from a year earlier.

He added that some loyal customers continued purchasing but may have paused a subscription for a month before resuming it, affecting reported metrics.

Fourth-quarter gross profit margin was 78.0%, compared with 79.9% a year earlier.

Aure attributed the decrease to product mix, higher inventory obsolescence expense, and increased shipping and warehouse-related costs.

Commissions and incentive expense represented 41.3% of revenue, down from 42.1% in the prior-year quarter, due to the timing and magnitude of promotional incentive programs and changes in the sales mix between customers and independent consultants.

Selling, general and administrative expenses were 32.7% of revenue, versus 33.9% a year ago.

Adjusted SG&A was 32.3% of revenue, compared with 33.3%.

GAAP operating income was $1.7 million, down from $2.1 million in the prior-year quarter.

Adjusted operating income declined to $1.8 million from $2.5 million.

GAAP net income was $1.3 million, or $0.10 per diluted share, compared with $2.0 million, or $0.15 per diluted share, a year earlier.

On an adjusted basis, net income was $1.4 million, or $0.11 per diluted share, compared with $2.3 million, or $0.17 per diluted share, in the fourth quarter of fiscal 2025.

Adjusted EBITDA declined to $2.7 million, or 6.5% of revenue, from $4.8 million, or 8.7% of revenue.

Terrence Moorehead, who recently joined LifeVantage as president and chief executive officer, said his early review of the business reinforced his conviction in its differentiated science, balance sheet and potential for growth.

He thanked Michael Beindorff for his stewardship during the leadership transition.

Moorehead said the company’s initial priorities will center on strengthening the...